The 2016 European Thyroid Association/European Group on Graves' orbitopathy guidelines for the management of graves' orbitopathy

Luigi Bartalena, Lelio Baldeschi, Kostas Boboridis, Anja Eckstein, George J. Kahaly, Claudio Marcocci, Petros Perros, Mario Salvi, Wilmar M. Wiersinga

Research output: Contribution to journalArticle

Abstract

Graves' orbitopathy (GO) is the main extrathyroidal manifestation of Graves' disease, though severe forms are rare. Management of GO is often suboptimal, largely because available treatments do not target pathogenic mechanisms of the disease. Treatment should rely on a thorough assessment of the activity and severity of GO and its impact on the patient's quality of life. Local measures (artificial tears, ointments and dark glasses) and control of risk factors for progression (smoking and thyroid dysfunction) are recommended for all patients. In mild GO, a watchful strategy is usually sufficient, but a 6-month course of selenium supplementation is effective in improving mild manifestations and preventing progression to more severe forms. High-dose glucocorticoids (GCs), preferably via the intravenous route, are the first line of treatment for moderate-to-severe and active GO. The optimal cumulative dose appears to be 4.5-5 g of methylprednisolone, but higher doses (up to 8 g) can be used for more severe forms. Shared decision-making is recommended for selecting second-line treatments, including a second course of intravenous GCs, oral GCs combined with orbital radiotherapy or cyclosporine, rituximab or watchful waiting. Rehabilitative treatment (orbital decompression surgery, squint surgery or eyelid surgery) is needed in the majority of patients when GO has been conservatively managed and inactivated by immunosuppressive treatment.

Original languageEnglish
Pages (from-to)9-26
Number of pages18
JournalEuropean Thyroid Journal
Volume5
Issue number1
DOIs
Publication statusPublished - Mar 1 2016

Fingerprint

Guidelines
Glucocorticoids
Therapeutics
Watchful Waiting
Strabismus
Graves Disease
Methylprednisolone
Eyelids
Immunosuppressive Agents
Selenium
Ointments
Decompression
Cyclosporine
Glass
Decision Making
Thyroid Gland
Radiotherapy
Smoking
Quality of Life

Keywords

  • Cyclosporine
  • Eyelid surgery
  • Glucocorticoids
  • Graves' orbitopathy
  • Orbital decompression
  • Orbital radiotherapy
  • Rituximab
  • Selenium
  • Squint surgery

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

Bartalena, L., Baldeschi, L., Boboridis, K., Eckstein, A., Kahaly, G. J., Marcocci, C., ... Wiersinga, W. M. (2016). The 2016 European Thyroid Association/European Group on Graves' orbitopathy guidelines for the management of graves' orbitopathy. European Thyroid Journal, 5(1), 9-26. https://doi.org/10.1159/000443828

The 2016 European Thyroid Association/European Group on Graves' orbitopathy guidelines for the management of graves' orbitopathy. / Bartalena, Luigi; Baldeschi, Lelio; Boboridis, Kostas; Eckstein, Anja; Kahaly, George J.; Marcocci, Claudio; Perros, Petros; Salvi, Mario; Wiersinga, Wilmar M.

In: European Thyroid Journal, Vol. 5, No. 1, 01.03.2016, p. 9-26.

Research output: Contribution to journalArticle

Bartalena, L, Baldeschi, L, Boboridis, K, Eckstein, A, Kahaly, GJ, Marcocci, C, Perros, P, Salvi, M & Wiersinga, WM 2016, 'The 2016 European Thyroid Association/European Group on Graves' orbitopathy guidelines for the management of graves' orbitopathy', European Thyroid Journal, vol. 5, no. 1, pp. 9-26. https://doi.org/10.1159/000443828
Bartalena, Luigi ; Baldeschi, Lelio ; Boboridis, Kostas ; Eckstein, Anja ; Kahaly, George J. ; Marcocci, Claudio ; Perros, Petros ; Salvi, Mario ; Wiersinga, Wilmar M. / The 2016 European Thyroid Association/European Group on Graves' orbitopathy guidelines for the management of graves' orbitopathy. In: European Thyroid Journal. 2016 ; Vol. 5, No. 1. pp. 9-26.
@article{8641916b2a074dde9e9a3ab84b0419d7,
title = "The 2016 European Thyroid Association/European Group on Graves' orbitopathy guidelines for the management of graves' orbitopathy",
abstract = "Graves' orbitopathy (GO) is the main extrathyroidal manifestation of Graves' disease, though severe forms are rare. Management of GO is often suboptimal, largely because available treatments do not target pathogenic mechanisms of the disease. Treatment should rely on a thorough assessment of the activity and severity of GO and its impact on the patient's quality of life. Local measures (artificial tears, ointments and dark glasses) and control of risk factors for progression (smoking and thyroid dysfunction) are recommended for all patients. In mild GO, a watchful strategy is usually sufficient, but a 6-month course of selenium supplementation is effective in improving mild manifestations and preventing progression to more severe forms. High-dose glucocorticoids (GCs), preferably via the intravenous route, are the first line of treatment for moderate-to-severe and active GO. The optimal cumulative dose appears to be 4.5-5 g of methylprednisolone, but higher doses (up to 8 g) can be used for more severe forms. Shared decision-making is recommended for selecting second-line treatments, including a second course of intravenous GCs, oral GCs combined with orbital radiotherapy or cyclosporine, rituximab or watchful waiting. Rehabilitative treatment (orbital decompression surgery, squint surgery or eyelid surgery) is needed in the majority of patients when GO has been conservatively managed and inactivated by immunosuppressive treatment.",
keywords = "Cyclosporine, Eyelid surgery, Glucocorticoids, Graves' orbitopathy, Orbital decompression, Orbital radiotherapy, Rituximab, Selenium, Squint surgery",
author = "Luigi Bartalena and Lelio Baldeschi and Kostas Boboridis and Anja Eckstein and Kahaly, {George J.} and Claudio Marcocci and Petros Perros and Mario Salvi and Wiersinga, {Wilmar M.}",
year = "2016",
month = "3",
day = "1",
doi = "10.1159/000443828",
language = "English",
volume = "5",
pages = "9--26",
journal = "European Thyroid Journal",
issn = "2235-0640",
publisher = "S. Karger AG",
number = "1",

}

TY - JOUR

T1 - The 2016 European Thyroid Association/European Group on Graves' orbitopathy guidelines for the management of graves' orbitopathy

AU - Bartalena, Luigi

AU - Baldeschi, Lelio

AU - Boboridis, Kostas

AU - Eckstein, Anja

AU - Kahaly, George J.

AU - Marcocci, Claudio

AU - Perros, Petros

AU - Salvi, Mario

AU - Wiersinga, Wilmar M.

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Graves' orbitopathy (GO) is the main extrathyroidal manifestation of Graves' disease, though severe forms are rare. Management of GO is often suboptimal, largely because available treatments do not target pathogenic mechanisms of the disease. Treatment should rely on a thorough assessment of the activity and severity of GO and its impact on the patient's quality of life. Local measures (artificial tears, ointments and dark glasses) and control of risk factors for progression (smoking and thyroid dysfunction) are recommended for all patients. In mild GO, a watchful strategy is usually sufficient, but a 6-month course of selenium supplementation is effective in improving mild manifestations and preventing progression to more severe forms. High-dose glucocorticoids (GCs), preferably via the intravenous route, are the first line of treatment for moderate-to-severe and active GO. The optimal cumulative dose appears to be 4.5-5 g of methylprednisolone, but higher doses (up to 8 g) can be used for more severe forms. Shared decision-making is recommended for selecting second-line treatments, including a second course of intravenous GCs, oral GCs combined with orbital radiotherapy or cyclosporine, rituximab or watchful waiting. Rehabilitative treatment (orbital decompression surgery, squint surgery or eyelid surgery) is needed in the majority of patients when GO has been conservatively managed and inactivated by immunosuppressive treatment.

AB - Graves' orbitopathy (GO) is the main extrathyroidal manifestation of Graves' disease, though severe forms are rare. Management of GO is often suboptimal, largely because available treatments do not target pathogenic mechanisms of the disease. Treatment should rely on a thorough assessment of the activity and severity of GO and its impact on the patient's quality of life. Local measures (artificial tears, ointments and dark glasses) and control of risk factors for progression (smoking and thyroid dysfunction) are recommended for all patients. In mild GO, a watchful strategy is usually sufficient, but a 6-month course of selenium supplementation is effective in improving mild manifestations and preventing progression to more severe forms. High-dose glucocorticoids (GCs), preferably via the intravenous route, are the first line of treatment for moderate-to-severe and active GO. The optimal cumulative dose appears to be 4.5-5 g of methylprednisolone, but higher doses (up to 8 g) can be used for more severe forms. Shared decision-making is recommended for selecting second-line treatments, including a second course of intravenous GCs, oral GCs combined with orbital radiotherapy or cyclosporine, rituximab or watchful waiting. Rehabilitative treatment (orbital decompression surgery, squint surgery or eyelid surgery) is needed in the majority of patients when GO has been conservatively managed and inactivated by immunosuppressive treatment.

KW - Cyclosporine

KW - Eyelid surgery

KW - Glucocorticoids

KW - Graves' orbitopathy

KW - Orbital decompression

KW - Orbital radiotherapy

KW - Rituximab

KW - Selenium

KW - Squint surgery

UR - http://www.scopus.com/inward/record.url?scp=84985017669&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84985017669&partnerID=8YFLogxK

U2 - 10.1159/000443828

DO - 10.1159/000443828

M3 - Article

VL - 5

SP - 9

EP - 26

JO - European Thyroid Journal

JF - European Thyroid Journal

SN - 2235-0640

IS - 1

ER -